Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma

Peking University

Status: Completed

Conditions: Kidney Cancer

Treatments: Procedure: Surgery treatment or local tumor destruction.

Study type: Observational

Funder types: Other

Identifiers

NCT06369519

2023#17-23

Details and patient eligibility

About

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are:

What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients?

Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Full description

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. This cohort study aims to identify prognostic factors, construct predictive nomograms, and optimize surgical treatment for sporadic BRCC patients. The main questions it aims to answer are:

What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? In this retrospective population-based cohort study, patients diagnosed with sporadic BRCC between 2000 and 2020 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Enrollment: 3,677 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years.
• Clinical diagnosis of localized BRCC (M0) from 2000 to 2020.
• Active follow-up.
• Complete clinicopathological information.

Exclusion criteria

• Diagnosed by autopsy or death certificate only.
• Tending to suffer from hereditary RCC, including those complicating with pancreatic neuroendocrine tumor (pNET) or hemangioblastoma.
• Unavailable key information.

Trial design

3,677 participants in 2 patient groups

Synchronous BRCC patients

Description:

Synchronous BRCC is defined as the second primary RCC emerges within 6 months from the diagnosis of the first primary RCC.

Treatment:

Procedure: Surgery treatment or local tumor destruction.

Metachronous BRCC patients

Description:

Metachronous BRCC develops beyond 6 months from the diagnosis of the first primary RCC.

Treatment:

Procedure: Surgery treatment or local tumor destruction.